US EditionPublished • loading... • Updated
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
Eli Lilly raised its 2025 earnings guidance to up to $23.70 per share and revenue to as much as $63.5 billion, driven by strong sales of Zepbound and Mounjaro.
- After reporting Q3 on Thursday, Eli Lilly and Co. raised full-year 2025 guidance to $21.80–$22.50 EPS and revenues of $63.0–$63.5 billion.
- Citing portfolio strength, Eli Lilly said the guidance bump reflected strong underlying business performance and favorable foreign exchange rates.
- Previously, Eli Lilly had guided earnings of $20.85–$22.10 and revenues of $60.0–$62.0 billion, compared to analysts' expectations of $22.50 and $61.63 billion.
- Reported amid earnings-season coverage, the update highlights that analysts' estimates typically exclude special items, a key factor comparing guidance to polls.
- As markets digested Federal Reserve minutes and mortgage applications data, international moves including Asia-Pacific, New Zealand interest rate decision and Germany economic indicators framed investor reactions.
Insights by Ground AI
13 Articles
13 Articles
Eli Lilly Again Boosts FY25 Outlook
While reporting financial results for the third quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2025, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.
Coverage Details
Total News Sources13
Leaning Left2Leaning Right2Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 22%
C 56%
R 22%
Factuality
To view factuality data please Upgrade to Premium
